SLC12A7

Across TCGA pan-cancer cohorts, SLC12A7 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SLC12A7 data layer compared with 28 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher SLC12A7 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SLC12A7 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

LUAD, LSCC, and HNSC are the cancer types where SLC12A7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	All	0.500	0.942	.002	23	view →
LSCC	OS	Median	II,III,IV	0.600	0.921	.004	11	view →
HNSC	OS	Median	All	0.380	1.000	.008	10	view →
CCRCC	DFS	Median	III,IV	1.000	0.821	.020	6	view →
PDAC	DFS	Median	All	0.696	0.827	.013	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SLC12A7–LUAD (DFS)

Open the LUAD breakdown →